CA2127537A1 - Use of fibroblast growth factors as neuroprotective and neuromodulatory agents - Google Patents

Use of fibroblast growth factors as neuroprotective and neuromodulatory agents

Info

Publication number
CA2127537A1
CA2127537A1 CA002127537A CA2127537A CA2127537A1 CA 2127537 A1 CA2127537 A1 CA 2127537A1 CA 002127537 A CA002127537 A CA 002127537A CA 2127537 A CA2127537 A CA 2127537A CA 2127537 A1 CA2127537 A1 CA 2127537A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
fibroblast growth
acidic
aggressiveness
agitation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002127537A
Other languages
English (en)
French (fr)
Inventor
Guillermo Gimenez Gallego
Pedro Cuevas Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Espana SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2127537A1 publication Critical patent/CA2127537A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002127537A 1992-11-23 1993-11-19 Use of fibroblast growth factors as neuroprotective and neuromodulatory agents Abandoned CA2127537A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP9202360 1992-11-23
ES09202360A ES2061380B1 (es) 1992-11-23 1992-11-23 Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.

Publications (1)

Publication Number Publication Date
CA2127537A1 true CA2127537A1 (en) 1994-06-09

Family

ID=8278876

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002127537A Abandoned CA2127537A1 (en) 1992-11-23 1993-11-19 Use of fibroblast growth factors as neuroprotective and neuromodulatory agents

Country Status (5)

Country Link
EP (1) EP0624094A1 (es)
JP (1) JPH07504205A (es)
CA (1) CA2127537A1 (es)
ES (1) ES2061380B1 (es)
WO (1) WO1994012201A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831117A (en) 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
DE69634907T2 (de) * 1995-04-25 2006-05-18 Ajinomoto Co., Inc. Fibroblastenwachstumsfragmente
JP4847634B2 (ja) * 1996-03-22 2011-12-28 ストライカー・コーポレーション 中枢神経系の虚血または外傷の機能的回復を増大させる方法
JP2002512627A (ja) * 1997-06-11 2002-04-23 アコーダ セラピーティックス Ｃｎｓ神経再生組成物及びその使用方法
AU8855798A (en) * 1997-07-03 1999-01-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel composition for treating, preventing and/or delaying ischemic cell death
JP3507884B2 (ja) * 2000-03-07 2004-03-15 新潟大学長 遺伝子発現を指標とする統合失調症の客観的診断法
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
US20090019557A1 (en) 2005-11-12 2009-01-15 Huda Akil Fgf2-related methods for diagnosing and treating depression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
JP2814529B2 (ja) * 1989-03-16 1998-10-22 味の素株式会社 虚血性脳障害治療薬
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration

Also Published As

Publication number Publication date
JPH07504205A (ja) 1995-05-11
ES2061380B1 (es) 1995-07-01
ES2061380A1 (es) 1994-12-01
WO1994012201A1 (en) 1994-06-09
EP0624094A1 (en) 1994-11-17

Similar Documents

Publication Publication Date Title
US5057494A (en) Method for preventing tissue damage after an ischemic episode
US4378347A (en) Composition for treating the heart for myocardial infarction
Sinson et al. Nerve growth factor administration attenuates cognitive but not neurobehavioral motor dysfunction or hippocampal cell loss following fluid‐percussion brain injury in rats
von Meyenburg et al. Regeneration and sprouting of chronically injured corticospinal tract fibers in adult rats promoted by NT-3 and the mAb IN-1, which neutralizes myelin-associated neurite growth inhibitors
Awad et al. Potential role of growth factors in the management of spinal cord injury
Liu et al. Neuroprotective effect of chronic infusion of basic fibroblast growth factor on seizure-associated hippocampal damage
AU2010213575B2 (en) Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease
CA2127537A1 (en) Use of fibroblast growth factors as neuroprotective and neuromodulatory agents
Katsuura et al. Preventive effect of cholecystokinin octapeptide on experimental amnesia in rats
AU2004226372A1 (en) Use of erythropoietin in stroke recovery
Cuevas et al. Acidic fibroblast growth factor prevents post-axotomy neuronal death of the newborn rat facial nerve
DE69232596T2 (de) Inhibitor von nebenwirkungen zur krebstherapy
US6194376B1 (en) Method for modulating inflammatory response comprising administering morphogen
US20240269343A1 (en) Use of immune modulators to improve nerve regeneration
Cuevas et al. Single topical application of human recombinant basic fibroblast growth factor (rbFGF) promotes neovascularization in rat cerebral cortex
US7753054B2 (en) Method of constructing spinal injury model monkey and utilization thereof
HUT76895A (en) Use of hyaluronic acid for preparing pharmaceutical compns. for treatment of disease and conditions associated with macrophage infiltration
Stichel et al. Scar modulation in subacute and chronic CNS lesions: Effects on axonal regeneration
US20220030851A1 (en) Modulating ischemic injury
DE69838399T2 (de) Präparation zur kontinuierlichen intravenösen verabreichung
US6780837B1 (en) Prevention of retinal injury and degeneration by specific factors
JP4790195B2 (ja) 組織再生剤
WO1992019256A1 (en) New medicinal use
Muniswami et al. Therapeutic effect of fibroblast growth factor and olfactory ensheathing cells in rat models of spinal cord injury
He et al. Macrophage and microglial cell response after common peroneal nerve cut and crush in C57BL/6J mice

Legal Events

Date Code Title Description
FZDE Dead